What exactly did BMO do on March 9, 2026 for Pfizer

BMO Capital reiterated an **Outperform** rating on Pfizer Inc. (PFE) on **March 9, 2026** after Phase 2 data, without publishing a new price target, per StreetInsider.

Does the BMO note count as a PFE upgrade or downgrade

No. The BMO action is a maintained Outperform. It is neither a PFE upgrade nor a PFE downgrade because the rating and published targets were not changed.

How should investors use the PFE analyst rating in decisions

Treat the **PFE analyst rating** reiterated by BMO as supportive but not decisive. Combine it with fundamentals, pipeline catalysts, and your risk profile before adjusting positions.

Where can I read the BMO note and check Pfizer’s price

Read the BMO coverage summary on StreetInsider [source](https://www.streetinsider.com/Analyst+Comments/BMO+Capital+Reiterates+Outperform+Rating+on+Pfizer+%28PFE%29+following+Ph2+data/26130568.html). Check live price context on Investing.com [source](https://uk.investing.com/equities/pfizer).

Analyst Ratings

BMO Maintains Outperform on Pfizer (PFE) March 2026

ByHuzaifa Zahoor March 10, 2026

BMO Capital maintained an Outperform rating on Pfizer Inc. (PFE) on March 9, 2026. The move is the only recent change in coverage and reflects BMO’s view after Phase 2 data, according to StreetInsider. The phrase PFE analyst rating guides this update and frames what investors should expect in near term. BMO left the rating unchanged and reported a modest market reaction of 0.77% ($0.20). We cover what the BMO action means for shareholders and how this fits into broader analyst coverage of Pfizer